Advisors Preferred LLC Acquires New Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Advisors Preferred LLC purchased 3,100 Thermo Fisher shares worth approximately $1.62 million during the second quarter, while institutional investors overall own 89.23% of the company.
• Thermo Fisher reported strong quarterly results, with EPS of $6.03 and revenue of $11.99 billion, exceeding estimates and representing 10.5% year-over-year revenue growth.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $619.41 price target, although insiders have sold $37.7 million of shares over the past 90 days.

Advisors Preferred LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 3,100 shares of the medical research company's stock, valued at approximately $1,623,000.

A number of other large investors also recently modified their holdings of TMO. KilterHowling LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $202,000. Fairtree Asset Management Pty Ltd acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $2,960,000. Oxford Financial Group LTD. LLC bought a new position in shares of Thermo Fisher Scientific during the second quarter valued at $425,000. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth $25,000. Finally, Portfolio Design Labs LLC bought a new stake in shares of Thermo Fisher Scientific in the second quarter worth $1,527,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total value of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. This trade represents a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $71,191,194.75. The trade was a 7.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 63,493 shares of company stock worth $37,657,681. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Jefferies Financial Group reaffirmed a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. HSBC downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating and decreased their target price for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, Piper Sandler raised their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $619.41.

Thermo Fisher Scientific Trading Up 2.4%

Shares of TMO stock opened at $628.24 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock has a 50 day simple moving average of $539.33 and a two-hundred day simple moving average of $508.86. The company has a market cap of $232.29 billion, a P/E ratio of 33.79, a PEG ratio of 2.50 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter last year, the firm posted $4.28 EPS. The company's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 10.11%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source